Document Type : Original Article
Authors
1 Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
2 Assistant Professor, Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
3 Interventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Background: Valvular heart disease is a significant and increasing global health challenge. Prosthetic valve thrombosis (PVT) following surgical valve replacement is one of the major causes of primary valve failure. This study aimed to determine the outcomes and complications of fibrinolytic therapy in patients with PVT.
Methods: In this cross-sectional study, 81 patients with PVT who underwent fibrinolytic therapy between 2008 and 2018 were enrolled. 87.6% of patients were treated with streptokinase and 12.4% with reteplase. All demographic and clinical data were collected from the patients’ medical records. The incidence of successful recovery and complications were evaluated.
Results: The records of 81 patients (43.2% male, mean age: 51.6 ± 13.9 years) were investigated. The results showed 59% and 35% of the patients had mitral and aortic PVT, respectively. While 12% of the patients had drug complications, 90% of them had a successful recovery. Stroke and severe hemorrhage were complications frequently reported by the patients treated with streptokinase (8% and 4% respectively). The patients treated with reteplase showed 100% successful recovery. On the other hand, 89% of the patients treated with streptokinase had successful recovery and 7% of the patients had a partial recovery.
Conclusion: Fibrinolytic agents can be an effective therapy with an excellent success rate for the management of PVT in patients after surgical valve replacement.
Keywords
)